Clinical Trial Update: JS207 Combination Therapy in Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of JS207 combination therapy for triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• JS207

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: RECRUITING